Literature DB >> 2542409

Signal transduction pathway for IL-1. Involvement of a pertussis toxin-sensitive GTP-binding protein in the activation of adenylate cyclase.

M Chedid1, F Shirakawa, P Naylor, S B Mizel.   

Abstract

Human Il-1 alpha induces the synthesis of kappa Ig L chains by the pre-B cell line 7OZ/3, IL-2R alpha by the human NK cell line YT, and PGE2 by human rheumatoid synovial cells. Pertussis toxin (PT) markedly inhibited all three IL-1-induced activation events. The inhibition by PT was associated with a decrease in IL-1-mediated cAMP production. PT also inhibited IL-1-stimulated cAMP production in crude membrane fractions from 7OZ/3, YT, and 3T3 fibroblasts. In addition, IL-1 stimulated GTPase activity present in the membranes IL-1-responsive cells. Furthermore, the IL-1-induced GTPase activity was sensitive to PT. PT induced the ADP-ribosylation of a 46-kDa substrate in membrane preparations from IL-1-responsive cells. Cholera toxin also induced the ADP-ribosylation of a 46-kDa substrate in the same membrane preparations. The present findings indicate that the IL-1R is linked to a PT-sensitive G protein that stimulates the activity of adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542409

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Evidence that responses of articular chondrocytes to interleukin-1 and basic fibroblast growth factor are not mediated by protein kinase C.

Authors:  K I Hulkower; H I Georgescu; C H Evans
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

Review 2.  Tumor necrosis factor regulation of major histocompatibility complex gene expression.

Authors:  D R Johnson; J S Pober
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

3.  Effect of cyclic GMP-dependent vasodilators on the expression of inducible nitric oxide synthase in vascular smooth muscle cells: role of cyclic AMP.

Authors:  M Boese; R Busse; A Mülsch; V Schini-Kerth
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

4.  Involvement of cyclic AMP-dependent protein kinases in the signal transduction pathway for interleukin-1.

Authors:  M Chedid; S B Mizel
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

5.  Role of a pertussis toxin sensitive G-protein in mediating the effects of phorbol esters on receptor activated cyclic AMP accumulation in Jurkat cells.

Authors:  I van der Ploeg; N Altiok; A Kvanta; C Nordstedt; B B Fredholm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

6.  Heat shock-mediated transient increase in intracellular 3',5'-cyclic AMP results in tumor specific suppression of membrane type 1-matrix metalloproteinase production and progelatinase A activation.

Authors:  Y Sawaji; T Sato; M Seiki; A Ito
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

7.  Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen.

Authors:  A Kimura; K T Mountzouros; P A Schad; W Cieplak; J L Cowell
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

8.  The IL-1 receptor and Rho directly associate to drive cell activation in inflammation.

Authors:  R Singh; B Wang; A Shirvaikar; S Khan; S Kamat; J R Schelling; M Konieczkowski; J R Sedor
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

9.  Interleukin-1 beta inhibition of insulin release in rat pancreatic islets: possible involvement of G-proteins in the signal transduction pathway.

Authors:  A M Rabuazzo; M Buscema; V Caltabiano; M Anello; C Degano; G Patanè; R Vigneri; F Purrello
Journal:  Diabetologia       Date:  1995-07       Impact factor: 10.122

10.  Interleukin-1 activates a novel protein kinase that phosphorylates the epidermal-growth-factor receptor peptide T669.

Authors:  M Kracht; M Shiroo; C J Marshall; J J Hsuan; J Saklatvala
Journal:  Biochem J       Date:  1994-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.